藍鼎國際(00582.HK)暫緩主席仰智慧一切行政及執行職務與權力
藍鼎國際(00582.HK)公布,於11月14日收到來自證監會知會公司的函件,證監會已於11月8日透過針對數名答辯人及Teamway(01239.HK)之呈請在香港原訟法庭展開法律程序,當中董事會主席兼執行董事仰智慧已在呈請中列為答辯人之一。
公司指出,為減輕股東及公眾之疑慮,董事會已議決暫緩仰智慧作為主席及執行董事的一切行政及執行職務及權力,自上周五(18日)起生效直至另行通知;並議決執行董事陳美思擔任董事會署理主席。
於暫緩期間,集團之日常業務營運及管理乃由集團其他四名執行董事及高級管理團隊進行,因此公司認為暫緩在任何重大方面將不會影響集團的日常營運,且集團業務將如常運作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.